← Browse by Condition
Medical Condition

lymphoma primary effusion

Total Trials
1
Recruiting Now
1
Trial Phases
Phase 2
NCT05907759 Phase 2
Recruiting

Daratumumab for Relapsed/Refractory Primary Effusion Lymphoma, Plasmablastic Lymphoma, and Multicentric Castleman Disease

Enrollment
28 pts
Location
United States
Sponsor
National Cancer Institute (NCI...
View Trial →